PET Scans ID Esophageal Cancers Benefiting From Chemo
- Posted by on May 21st, 2008 filed in Medicine News
(PET) accurately identifies positive metabolic responses to chemotherapy
in patients with esophageal cancer and helps doctors tailor treatment,
says a German study.
| ADVERTISEMENT |
“This is the first study to apply PET results from early metabolic
response assessment to clinical emergency medicine news
in the treatment of common
solid tumors,” Ken Herrmann, a resident in the department of nuclear
medicine at Technical University in Munich, said in a prepared
statement.
“The outcome for metabolic medicine news turned out to be remarkably
favorable compared to metabolic non-responders. Our results showed that
PET helps select patients who are benefiting from chemotherapy. Based on
our early response assessment, the course is set for tailoring
multimodality treatment on the basis of tumor biology.”
Herrmann added that PET-response-guided treatment also “helped
pharma the health of inefficient chemotherapy to patients with
no metabolic response, without compromising their outcome.”
In the United States, more than 14,000 people are expected to die from
esophageal cancer this year, and more than 15,000 new cases will be
diagnosed, according to background information in a news release about the
study.
The study was presented this week at the Society of Nuclear Medicine's
annual meeting, in Washington, D.C.
More information
The
American Cancer Society has more about esophageal cancer.
Leave a Comment
You must be logged in to post a comment.